BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products
1. BON signed a 24-month contract worth $18 million with Huahai Keyuan. 2. The cooperation targets weight management and metabolic health across Greater China. 3. BON's second-generation Apple Series shows 80% higher bioactivity, enhancing efficacy. 4. Comparable products have seen over $40 million in monthly sales. 5. BON aims for revenue growth, leveraging advanced extraction technology.